

# REPORT OF THE 383<sup>rd</sup> CELL EXCHANGE NOVEMBER 5, 2014

B-cell Lines	507-508
Cells	1529-1532
Serum	1157-1160

## B-cell Line Exchange #254

The results for B-cell Line Exchange #254 are summarized on Tables 1-2 and individual laboratory results reported for each sample are listed in

Tables 3-6. The haplotype frequencies used in this report are from the NMDP Bioinformatics website, <http://bioinformatics.nmdp.org/>.

**Ter-507.** The consensus type for this Japanese sample is DRB1\*09:01-DRB4\*01:03-DQA1\*03-DQB1\*03:03-DPA1\*01:03-DPB1\*02:01-A\*24:02-A\*26:02-B\*40:06-B\*54:01-C\*01:02-C\*08:01. The probable associations in this sample are A\*24:02-B\*54:01-DRB1\*09:01 and A\*26:02-B\*40:06-DRB1\*09:01, with respective frequencies of 0.00098 and 0.00114, exclusively in Asians.

This sample is KOZ, the reference cell for DQB1\*03:03:02:01. It was studied in previous workshops as IHW#9310. DQB1\*03:03 was assigned by 48%, with 2 labs assigning DQB1\*03:03:02. DRB1\*09:01 was reported by 38%, with an additional 7 labs reporting DRB1\*09:01/21. DRB1\*09:21 differs from DRB1\*09:01 in exon 4 by a single nucleotide substitution at codon 196 (CAG → CGG), resulting in an amino acid change from glutamine to arginine. Labs were split in the assignment for DQA1, as 14 labs reported DQA1\*03:02 and 12 labs assigned DQA1\*03:02/03. DQA1\*03:02 was observed in 2 previous DRB1\*09:01-DRB4\*01:03 exchange cells, Ter 383 (same as Ter 324) and Ter 205.

B\*54:01 was assigned by 44%, with 3 labs reporting B\*54:01:01. B\*40:06 (47%) was reported as the second B-locus type. A\*24:02 (43%) and A\*26:02 (52%) were the A-locus types.

**Ter-508.** The consensus type for this homozygous Caucasian sample is DRB1\*01:01-DQA1\*01:01-DQB1\*05:01-DPA1\*02:01-DPB1\*13:01-A\*24:02-B\*51:01-C\*12:03. The B\*51:01-C\*12:03-DRB1\*01:01-DQB1\*05:01 association in this cell is found to be rare and exclusively observed in Caucasians, with HF=0.00015.

This sample is KAS116, a reference cell for DPB1\*13:01:01, DQA1\*01:01:01, DQB1\*05:01:01:01, DRB6\*01:01, MICA\*006, and MICB\*005:02:01. It was also previously studied in the workshops as IHW#9003. DPB1\*13:01 was assigned by 81%, with 2 labs assigning DPB1\*13:01:01. DQA1\*01:01 and DQB1\*05:01 were reported by 37% and 53%, respectively. DRB1\*01:01 was reported by only 39%, a relatively low detection level compared to other DR1 exchange cells, such as Ter 478 and Ter 479, in which DRB1\*01:01 was assigned by 74% and 61%, respectively (1, 2). The low detection level in this study may be due to a number of labs (n=6) assigning DRB1\*01:01/50.

A\*24:02 (43%), B\*51:01 (41%), and C\*12:03 (46%) were the assigned class I types. B\*51:01:01 and C\*12:03:01 were each assigned by 3 labs.

### References:

1. Lau M, Locke A, Cecka JM, and Reed EF. Report of the 368<sup>th</sup> Cell Exchange. October 3, 2012.
2. Lau M, Locke A, Cecka JM, and Reed EF. Report of the 370<sup>th</sup> Cell Exchange. February 6, 2013.

**Table 1: Summary of the 254th B-cell Line Exchange**

**Ter-507**

		<b>61 LABS - DRB1</b>		<b>40 LABS - DRB4</b>		<b>35 LABS - DQA1</b>		<b>58 LABS - DQB1</b>		<b>15 LABS - DPA1</b>		<b>31 LABS - DPB1</b>							
<b>DNA Typing - class II</b>			%(n)				%(n)		%(n)		%(n)		%(n)						
		DRB1*09:01:02	5	(3)	DRB4*01:03	48	(19)	DQA1*03:01:01G	3	(1)	DQB1*03:03:02	3	(2)	DPA1*01:03:01	7	(1)	DPB1*02:01:02	6	(2)
		DRB1*09:01:02G	5	(3)	DRB4*01:01+	12	(5)	DQA1*03:02	40	(14)	DQB1*03:03:02G	3	(2)	DPA1*01:03	80	(12)	DPB1*02:01:02G	10	(3)
		DRB1*09:01P	2	(1)	DRB4*01	25	(10)	DQA1*03:02/03	34	(12)	DQB1*03:03	42	(24)	DPA1*01	13	(2)	DPB1*02:01P	6	(2)
		DRB1*09:01	26	(16)	DRB4*+	15	(6)	DQA1*03	23	(8)	DQB1*03:03+	16	(9)				DPB1*02:01	71	(22)
		<i>DRB1*04:82</i>	2	(1)						DQB1*03 (DQ9)	3	(2)					DPB1*02:01/*+	6	(2)
		DRB1*09:01/21	11	(7)						<i>DQB1*03 (DQ8)</i>	2	(1)							
		DRB1*09:01+	11	(7)						DQB1*03	31	(18)							
		DRB1*09	38	(23)															
<b>Serology - class II</b>			%(n)																
		<b>4 LABS - DR</b>																	
		DR9	100	(4)															
		DR53	100	(4)															
<b>DNA Typing - class I</b>			%(n)				%(n)				%(n)		%(n)						
		<b>39 LABS - HLA-A</b>			<b>39 LABS - HLA-B</b>			<b>39 LABS - HLA-C</b>											
		A*24:02:01G	2	(1)	B*40:06:01:01	3	(1)	C*01:02:01	3	(1)									
		A*24:02	41	(16)	B*40:06:01G	3	(1)	C*01:02:01G	5	(2)									
		A*24:02+	13	(5)	B*40:06	41	(16)	C*01:02	20	(8)									
		A*24	44	(17)	<i>B*40:02</i>	2	(1)	<i>C*01:22</i>	3	(1)									
					<i>B*54:16</i>	3	(1)	C*01:02+	25	(10)									
					B*40:06/256N	8	(3)	C*01	44	(17)									
					B*40:04+	5	(2)												
					B*40 (B61)	8	(3)												
				B*40	28	(11)													
	A*26:02:01	8	(3)	B*54:01:01	8	(3)	C*08:01:01	3	(1)										
	A*26:02	44	(17)	B*54:01:01G	3	(1)	C*08:01:01G	8	(3)										
	A*26:02+	10	(4)	B*54:01	33	(13)	C*08:01	20	(8)										
	<i>A*26:60N</i>	2	(1)	<i>B*54:16</i>	3	(1)	<i>C*08:33</i>	3	(1)										
	A*26	36	(14)	B*54:01+	13	(5)	C*08:01+	23	(9)										
				B*54	41	(16)	C*08	43	(17)										



**Table 3: Individual laboratory results for B-cell #507-Class II**

Center	Investigator	DRB1		DRB4	DQA1		DQB1		DPA1		DPB1		METHOD
5488	Adams, Sharon	*09:01:02/21		*01	*03:02		*03:03:02				*02:01:02		SSO, SBT, SSP
4691	Ajlan, Abdula	*09:01/09/15	*09:01/07+				*03	*03					SSO, SBT
8038	Cao, Kai	*09:01/21		*01:01/03/06	*03:02/03		*03:03:02		*01:03		*02:01		SSO, SBT
774	Cecka, J. Mich	*09		*01:03	*03:02		*03		*01:03		*02:01		SSP
8070	Chang, Uckjin	*09											P-SSP
9916	Charlton, Ron	*09:01:02		*01:03			*03:03/65	*03:03/65					SSP, SBT
9916	Charlton_LR	NT											SSP
4492	Charron, D.	*09:01/09/18+	*09:01/15	*01:03	*03:02/03		*03:03/90N+		*01:03		*02:01/*141:01/+		P-SSO, SSP
3224	Chen, Dongfen	*09:01:02G		*01:03	*03:01:01G		*03:03		*01:03		*02:01		SSO, SSP, SBT
8021	Clark, Brendan	*09:01		*01			*03:03				*02:01		P-SSP, RVSSO
3632	Colombe, Beth	*09:01	*09:01/23	*01:03	*03:02		*03:03						SSOP, SSP
5130	Costeas, Paul	*09:01	*09:01	*01:03	*03:02	*03:02/03	*03:03	*03:03					SSO, SSP
779	Daniel, Claud	*09		*01	*03:02		*03:03		*01:03		*02:01		P-SSP, SSO
5219	Daniel, Dolly	*09	*09				*03	*03					SSOP
3766	Dunn, Paul	*09		*01	*03:02/03		*03		*01		*02:01		RT-PCR, SSO, SSP
5214	Eckels/CPMC	*09		*01	*03		*03 (DQ8)	*03 (DQ9)	*01:03		*02:01P		SSOP
3135	Enczmann, J	*09:01		*01:03			*03:03				*02:01		SBT, P-SSP, P-SSO
762	Fischer, Got	*09:01/07/12+		*01:03	*03:02		*03:03/98				*02:01		SSO, SSP, SBT
4079	Fort, Marylis	*09:01/21	*09:01/09+		*03:03/02		*03:03/31/33+				*02:01		SSP, SSO
792	Gandhi, Manis	*09:01		*01:03	*03:02		*03:03				*02:01		SSO, SSP
8043	Gideoni, Osna	*09:01			*03:02		*03:03		*01:03		*02:01		SSP
9002	Gideoni_LR	*09					*03						SSO, SSP
910	Hahn, Amy B.	*09		*01	*03:02		*03:03						SSP
810	Hamdi, Nuha	*09:01/04/05	*09:01/04+	*01:01/03/06	*03:02/03	*03:02/03	*03:02/03/31	*03:03/31+					SSO
2344	Hurley/Hartz	*09:01:02G	*09:01:02G		*03:02	*03:02	*03:03:02G	*03:03:02G	*01:03:01	*01:03:01	*02:01:02G	*02:01:02G	SBT, SSOP
771	Israel, Shosh	*09:01					*03:03						SSP
9003	Israel_LR	*09					*03						P-SSO
794	Jaatinen, Tai	*09:01		*01:03	*03:02/03		*03:03		*01:03		*02:01/*141:01		SBT, SSO, SSP
5891	Jiang, Yueqin	*09:01/21	*09:01/21				*03:03/90N+	*03:03/90N+					P-SBT
2847	Kihara, Masaaki	*09											RVSSO
4337	Kim, Tai-Gyu	*09:01	*09:01				*03:03	*03:03			*02:01	*02:01	SBT, SSP
168	Klein, Tirza	*09:01					*03:03						P-SSO, SSP
9000	Klein_LR	*09					*03						P-SSO, SSP
87	Land, Geoffre	*09:01	*09:01	*01:03	*03:02	*03:02	*03:03	*03:03			*02:01	*02:01	SBT, SSO, SSP
725	Lardy, N.M.	*09		*+	*03		*03						SSO
278	Lee, Jar-How	*09:01/21		*01:03	*03:02/03		*03:03/33/34+		*01:03		*02:01		SSP, RVSSOP
6649	Lim, Young Ae	*09		*+									SSP
274	Lo, Raymundo	*04:82	*12:35		*03:02	*03:02	*03	*03	*01:03	*01:03	*02:01	*02:01	SSO
731	Loewenthal, R	*09:01:02					*03:03	*03:03					SBT, SSO
759	Lopez-Cepero	*09:01/04/05+		*01:01/03/06+	*03:02/03		*03:03/31/33+		*01:03		*02:01P		RVSSO
8029	Mani, Rama	*09	*09				*03	*03					SSO
8052	Marcos, Cintia Y	*09	*09		*03:02/03	*03:02/03	*03	*03					P-SSO
206	McAlack-Hana	*09		*01	*03		*03 (DQ9)						RVSSOP
8042	Muncher, Lior	*09					*03:03						SSO, SSP
9001	Muncher_LR	*09					*03						SSO, SSP
3966	Permpikul&Ve	*09:01		*01:03			*03:03						P-SSP

**Table 3: Individual laboratory results for B-cell #507-Class II**

Center	Investigator	DRB1		DRB4	DQA1		DQB1		DPA1		DPB1		METHOD
2400	Phelan, Donna	*09:01/21		*01	*03:02/03		*03:03				*02:01:02G		SSO, SBT, SSP
8001	Rao, Prakash	*09:01		*01:03	*03		*03:03				*02:01		RVSSO, SSP
3753	Reed, Elaine	*09:01/21	*09:01/21	*01:01/03/06+	*03:02/03	*03:02/03	*03:03	*03:03					SBT, SSO
3519	Renac, Virg	*09:01		*01:03	*03:02	*03:03	*03:03				*02:01		SBT, P-SSP
3519	Renac, Virg_LR	*09					*03				*02:01		P-SSP
1160	Rosen-Bronson	*09:01/12/21		*01:03			*03						SSO, SSP, SBT
793	Rubocki, Rona	*09		*+	*03		*03 (DQ9)				*02:01		SSP
4251	Schiller, J	*09:01	*09:01	*01:03/06/08	*03	*03	*03:03	*03:03	*01	*01	*02:01:02G	*02:01:02G	P-RVSSO, SBT
8068	Shanmugam, He	*09		*+			*03						P-SSP
1108	Sutherland, L	*09	*09	*01	*03	*03	*03	*03					SSOP
747	Tiercy, Jean-	*09:01:02G		*01:03	*03:02/03		*03:03:02G				*02:01:02		SSO, SSP, SBT
5451	Tilanus, Marc	*09:01:02		*+			*03						SBT, SSP
5462	Turner, E.V.	*09:01P		*01:03			*03:03/86				*02:01		SSP, SSO, SBT
5642	Varnavidou-N	*09:01/09/10+		*+			*03:03						P-SSP
3511	Zeevi, Adrian	*09:01		*01:03	*03:02		*03:03				*02:01		RVSSOP, SSP

CTR	DIRNAME	DR9		DR53			DQ3		OTHER
4492	Charron, D.	+		+			+		DR10
910	Hahn, Amy B.	+		+			+		DR10, DQ1
4908	Kvam, Vonnett	+		+			DQ9		DR11, DR52
54	Pancoska, Car	+		+			+		
793	Rubocki, Rona	NT							

**Table 4: Individual laboratory results for B-cell #507-Class I**

Center	Investigator	HLA-A		HLA-B		HLA-C		METHOD
5488	Adams, Sharon	*24:02	*26:02:01	*40:06	*54:01:01	*01	*08	SSO, SBT, SSP
4691	Ajlan, Abdula	*24:02	*26:02	*40:06	*54:01	*01:02/85	*08:01/22/99+	SSO, SBT
8038	Cao, Kai	*24:02	*26:02:01	*40:06	*54:01:01	*01:02/85	*08:01/22/99/102	SSO, SSP, SBT
774	Cecka, J. Mich	*24	*26	*40	*54	*01	*08	SSP
9916	Charlton, Ron	*24:02	*26:02	*40:06:01:01	*54:01:01	*01:02:01	*08:01:01	SSP, SBT
9916	Charlton_LR	NT						SSP
4492	Charron, D.	*24:02/*135:02+	*26:02	*40:06/70/268+	*54:01/29+	*01:02/40/44+	*08:01/78/79+	P-SSO, SSP
3224	Chen, Dongfen	*24:02	*26:02	*40:06	*54:01	*01:02:01G	*08:01:01G	SSO, SSP, SBT
8021	Clark, Brendan	*24:02+	*26:02/40	*40:04+	*54:01+	*01:02+	*08:01+	P-SSP, RVSSO
3632	Colombe, Beth	*24	*26	*40	*54	*01	*08	SSOP, SSP
5130	Costeas, Paul	*24:02	*26:02	*40:06/70	*54:01/17	*01:02/28/31	*08:01/57	SSO, SSP
779	Daniel, Claud	*24	*26	*40:02	*54	*01	*08	P-SSP, SSO
5219	Daniel, Dolly	*24	*26	*40	*54	*01	*08	SSO
3766	Dunn, Paul	*24	*26:02/40	*40:04+	*54	*01	*08	RT-PCR, SSO, SSP
5214	Eckels/CPMC	*24	*26	*40 (B61)	*54	*01	*08	SSO
3135	Enczmann, J	*24:02	*26:02	*40:06	*54:01	*01:02	*08:01	SBT, P-SSP, P-SSO
792	Gandhi, Manis	*24:02	*26:02	*40:06	*54:01	*01:02	*08:01	SSO, SSP
810	Hamdi, Nuha	*24:02/02Q/09N	*26:02/40	*40:06	*54:01/17/29	*01:02/03/07	*08:01/08/16	SSO
2344	Hurley/Hartz	*24:02:01G	*26:02:01	*40:06:01G	*54:01:01G	*01:02:01G	*08:01:01G	SBT, SSOP
794	Jaatinen, Tai	*24:02	*26:02	*40:06	*54:01	*01:02	*08:01/22	SBT, SSO, SSP
5891	Jiang, Yueqin	*24:02/232N/252N	*26:02	*40:06/256N	*54:01	*01:02/43/64+	*08:01/22/89N/99+	P-SBT
2847	Kihara, Masaaki	*24	*26	*40	*54	*01	*08	RVSSO
4337	Kim, Tai-Gyu	*24:02	*26:02	*40:06	*54:01	*01:02	*08:01	SBT, SSP
278	Lee, Jar-How	*24:02/02Q/135+	*26:02	*40:06	*54:01/29	*01:02/25/26/27/29+	*08:01	SSP, RVSSOP
274	Lo, Raymundo	*24	*26	*54:16	*54:16	*01:22	*08:33	SSO
8029	Mani, Rama	*24	*26	*40	*54	*01	*08	SSO
8052	Marcos, Cintia Y	*24	*26:02/40/60N	*40	*54	*01	*08	P-SSO
206	McAlack-Hana	*24	*26	*40 (B61)	*54	*01	*08	RVSSOP
8042	Muncher, Lior	*24:02	*26:02	*40:06	*54:01	*01:02	*08:01	SSO, SSP
9001	Muncher_LR	*24	*26	*40	*54	*01	*08	SSO, SSP
54	Pancoska, Ca	*24	*26:60N	*40 (B61)	*54	*01	*08	RVSSO
3966	Permpikul&Ve	*24	*26	*40	*54	*01	*08	P-SSP
2400	Phelan, Donna	*24:02	*26:02	*40:06	*54:01	*01:02/85	*08:01	SSO, SBT, SSP
3753	Reed, Elaine	*24:02	*26:02	*40:06	*54:01	*01:02/43/64+	*08:01/16/22+	SBT, SSO
3519	Renac, Virginie	*24:02	*26:02	*40:06	*54:01	*01:02	*08:01	SBT, P-SSP
3519	Renac, Virginie_LR	*24	*26	*40	*54	*01	*08	P-SSP
4251	Schiller, J	*24:02	*26:02	*40:06	*54:01	*01:02	*08:01:01G	P-RVSSO, SBT
8068	Shanmugam, He	*24	*26	*40	*54	*01	*08	P-SSP
1108	Sutherland, L	*24	*26	*40	*54	*01	*08	SSO
5462	Turner, E.V.	*24:02	*26:02	*40:06	*54:01	*01:02	*08:01	SSP, SSO, SBT

**Table 5: Individual laboratory results for B-cell #508-Class II**

Center	Investigator	DRB1		DRB3	DQA1		DQB1		DPA1		DPB1		METHOD
5488	Adams, Sharon	*01:01:01			*01:01/12		*05:01:01				*13:01:01		SSO,SBT,SSP
4691	Ajlan,Abdula	*01:01	*01:01/40N				*05	*05					SSO,SBT
8038	Cao,Kai	*01:01/50			*01:01/04+		*05:01:01		*02:01		*13:01/*107:01		SSO,SBT
774	Cecka,J.Mich	*01:01/22/29+			*01:01/12		*05		*02:01		*13:01/*160:01		SSP
8070	Chang, Uckjin	*01											P-SSP
9916	Charlton,Ron	*01:01:01/50	*01:01:01/50				*05:01/20+	*05:01/03+					SSP,SBT
9916	Charlton_LR	*01					*05						SSP
4492	Charron,D.	*01:01/47/49+			*01:01/04+		*05:01/45+		*02:01		*13:01/*107:01/+		P-SSO,SSP
3224	Chen,Dongfen	*01:01:01G			*01:01:01G		*05:01		*02:01		*13:01:01G		SSO,SSP,SBT
8021	Clark,Brendan	*01:01					*05:01				*13:01		P-SSP,RVSSO
3632	Colombe,Beth	*01:01			*01:01		*05:01						SSOP,SSP
5130	Costeas,Paul	*01:01/18/36	*01:01/18+		*01:01	*01:01	*05:01	*05:01					SSO,SSP
779	Daniel,Claud	*01			*01:01		*05		*02:01		*13:01		P-SSP,SSO
5219	Daniel,Dolly	*01	*01				*05	*05					P-SSOP
3766	Dunn,Paul	*01			*01		*05		*02		*13:01		RT-PCR,SSO,SSP
5214	Eckels/CPMC	*01			*01		*05		*02:01		*13:01P		SSOP
3135	Enczmann,J	*01:01					*05:01				*13:01		SBT,P-SSP,P-SSO
762	Fischer,Got	*01:01/07/22+			*01:01		*05:01				*13:01/*107:01		SSO,SSP,SBT
4079	Fort,Maryliss	*01:01/50	*01:01/40N+		*01:01/04+		*05:01/07+				*13:01		SSP,SSO
792	Gandhi,Manis	*01:01			*01:01		*05:01				*13:01		SSO,SSP
8043	Gideoni,Osna	*01:01			*01:01		*05:01		*02:01		*13:01		SSP
9002	Gideoni_LR	*01					*05						SSO,SSP
910	Hahn,Amy B.	*01			*01:01		*05:01						SSP
810	Hamdi,Nuha	*01:01/05/07	*01:01/05+		*01:01/04+	*01:01/04+	*05:01/12+	*05:01/07+					SSO
2344	Hurley/Hartz	*01:01:01G	*01:01:01G		*01:01:01	*01:01:01	*05:01:01G	*05:01:01G	*02:01:01	*02:01:01	*13:01:01G	*13:01:01G	SBT,SSOP
771	Israel,Shosh	*01:01					*05:01						SSP
9003	Israel_LR	*01					*05						SSO
794	Jaatinen,Tai	*01:01			*01:01/04+		*05:01		*02:01		*13:01/*107:01		SBT,SSO,SSP
5891	Jiang,Yueqin	*01:01/50	*01:01/50				*05:01	*05:01					P-SBT
2847	Kihara,Masaaki	*01											rSSO
4337	Kim,Tai-Gyu	*01:01	*01:01				*05:01	*05:01			*13:01	*13:01	SBT,SSP
168	Klein,Tirza	*01:01					*05:01						P-SSO,SSP
9000	Klein_LR	*01					*05						P-SSO,SSP
87	Land,Geoffre	*01:01	*01:01		*01:01	*01:01	*05:01	*05:01			*13:01	*13:01	SBT,SSO,SSP
725	Lardy,N.M.	*01			*01		*05						SSO
278	Lee,Jar-How	*01:01/50			*01:01/04+		*05:01/12+		*02:01		*13:01/*160:01		SSP,RVSSOP
6649	Lim,Young Ae	*01											SSP
274	Lo,Raymundo	*01:02	*01:02		*01	*01	*05:01	*05	*02:01	*02:01	*13:01	*13:01	SSO
731	Loewenthal,R	*01:01:01/50					*05:01:01						SBT,SSO
759	Lopez-Cepero	*01:01/05/07+			*01:01/04+		*05:01/07+		*02:01		*13:01P		RVSSO
8029	Mani,Rama	*01	*01				*05	*05					SSO
8052	Marcos,Cintia Y	*01	*01		*01:01/04+	*01:01/04+	*05	*05					P-SSO
206	McAlack-Hana	*01			*01		*05	*05					RVSSOP
8042	Muncher,Lior	*01:01					*05:01						SSO,SSP
9001	Muncher_LR	*01					*05						SSO,SSP
3966	Permpikul&Ve	*01:01					*05:01						P-SSP

**Table 5: Individual laboratory results for B-cell #508-Class II**

Center	Investigator	DRB1		DRB3	DQA1		DQB1		DPA1		DPB1		METHOD
2400	Phelan, Donna	*01:01			*01:01:01G		*05:01				*13:01:01G		SSO, SBT, SSP
8001	Rao, Prakash	*01:01/07			*01		*05:01				*13:01		RVSSO, SSP
3753	Reed, Elaine	*01:01	*01:01		*01:01/04+	*01:01/06+	*05:01	*05:01					SBT, SSO
3519	Renac, Virginie	*01:01	*01:50		*01:01		*05:01				*13:01		SBT, P-SSP
3519	Renac, Virginie_LR	*01					*05				*13:01		SSP
1160	Rosen-Bronson	*01					*05:01						SSO, SSP, SBT
793	Rubocki, Rona	*01			*01		*05				*13:01		SSP
4251	Schiller, J	*01:01:01G	*01:01:01G		*01	*01	*05:01	*05:01	*02	*02	*13:01:01G	*13:01:01G	P-RVSSO, SBT
8068	Shanmugam, He	*01					*05						P-SSP
1108	Sutherland, L	*01	*01	*03	*01	*01	*05	*05					SSOP
747	Tiercy, Jean-	*01:01:01			*01:01/04+		*05:01:01				*13:01:01		SSO, SSP, SBT
5451	Tilanus, Marc	*01:01:01					*05						SBT, SSP
5462	Turner, E.V.	*01:01P					*05:01/44+				*13:01P		SSP, SSO, SBT
5642	Varnavidou-N	*01:01/10	*01:01/10				*05:01						P-SSP
3511	Zeevi, Adrian	*01:01			*01:01		*05:01				*13:01		RVSSOP, SSP

CTR	DIRNAME	DR1		DR52			DQ1		OTHER
4492	Charron, D.	+					+		DR10, DR13
910	Hahn, Amy B.	+					+		
4908	Kvam, Vonnett	+					+		DR103, DQ3
54	Pancoska, Car	+					+		
793	Rubocki, Rona	+					+		



**Table 6: Individual laboratory results for B-cell #508-Class I**

Center	Investigator	HLA-A		HLA-B		HLA-C		METHOD
5488	Adams, Sharon	*24:02		*51:01:01		*12:03:01		SSO, SBT, SSP
4691	Ajlan, Abdula	*24:02	*24:02	*51:01	*51:01	*12:03	*12:03	SSO, SBT
8038	Cao, Kai	*24:02		*51:01:01		*12:03:01		SSO, SBT
774	Cecka, J. Mich	*24		*51		*12		SSP
9916	Charlton, Ron	*24:02		*51:01		*12:03:01:01		SSP, SBT
9916	Charlton_LR	*24	*24/*23:57	*51		*12		SSP
4492	Charron, D.	*24:02/*135:02+		*51:01/152/154+		*12:03/100/107		P-SSO, SSP
3224	Chen, Dongfen	*24:02		*51:01		*12:03		SSO, SSP, SBT
8021	Clark, Brendan	*24:02+		*51:01+		*12:03+		P-SSP, RVSSO
3632	Colombe, Beth	*24		*51		*12		SSOP, SSP
5130	Costeas, Paul	*24:02	*24:02	*51:01/84/87/94	*51:01/84/87/94	*12:03	*12:03	SSO, SSP
779	Daniel, Claud	*24		*51		*12		P-SSP, SSO
5219	Daniel, Dolly	*24	*24	*51	*51	*12	*12	P-SSOP
3766	Dunn, Paul	*24		*51		*12:03+		RT-PCR, SSO, SSP
5214	Eckels/CPMC	*24		*51		*12		SSOP
3135	Enczmann, J	*24:02		*51:01		*12:03		SBT, P-SSP, P-SSO
792	Gandhi, Manis	*24:02		*51:01		*12:03		SSO, SSP
810	Hamdi, Nuha	*24:02/02Q/05	*24:02/02Q/05	*51:01/11N/24	*51:01/11N/24	*12:02/03/06	*12:03/06/07	SSO
2344	Hurley/Hartz	*24:02:01G	*24:02:01G	*51:01:01	*51:01:01	*12:03:01G	*12:03:01G	SBT, SSOP
794	Jaatinen, Tai	*24:02		*51:01		*12:03		SBT, SSO, SSP
5891	Jiang, Yueqin	*24:02/232N/252N	*24:02/232N/252N	*51:01	*51:01	*12:03	*12:03	P-SBT
2847	Kihara, Masaaki	*24		*51		*12		RVSSO
4337	Kim, Tai-Gyu	*24:02	*24:02	*51:01	*51:01	*12:03	*12:03	SBT, SSP
278	Lee, Jar-How	*24:02Q/21/74/98+		*51:01/70/91/94+		*12:03/23/34		SSP, RVSSOP
274	Lo, Raymundo	*24	*24	*51	*51	*12	*12	SSO
8029	Mani, Rama	*24	*24	*51	*51	*12	*12	SSO
8052	Marcos, Cintia Y	*24	*24	*51	*51	*12	*12	P-SSO
206	McAlack-Hana	*24	*24	*51	*51	*12	*12	RVSSOP
8042	Muncher, Lior	*24:02		*51		*12:03		SSO, SSP
9001	Muncher_LR	*24		*51		*12		SSO, SSP
54	Pancoska, Ca	*24		*51		*12		RVSSO
3966	Permpikul&Ve	*24		*51		*12		P-SSP
2400	Phelan, Donna	*24:02		*51:01		*12:03		SSO, SBT, SSP
3753	Reed, Elaine	*24:02	*24:02	*51:01	*51:01	*12:03	*12:03	SBT, SSO
3519	Renac, Virginie	*24:02		*51:01		*12:03		SBT, P-SSP
3519	Renac, Virginie_LR	*24		*51		*12		P-SSP
4251	Schiller, J	*24:02	*24:02	*51:01	*51:01	*12:03	*12:03	P-RVSSO, SBT
8068	Shanmugam, He	*24		*51		*12		P-SSP
1108	Sutherland, L	*24	*24	*51	*51	*12	*12	SSOP
5462	Turner, E. V.	*24:02		*51:01		*12:03		SSP, SSO, SBT

## Cell Exchange #383

The results for Cell Exchange #383 are summarized in Table 7 and Table 8. Molecular typing results for individual laboratories are listed in

Tables 9-12 for each sample and individual serology results for each sample are listed in Table 13.

**Cell 1529.** The consensus type for this Hispanic sample is A\*26:01(A26)-A\*30:01(A30)-B\*38:01(B38)-B\*49:01(B49)-C\*07:01(Cw7)-C\*12:03. The likely associations in this cell are B\*49:01-C\*07:01 and B\*38:01-C\*12:03, with respective frequencies of 0.02257 and 0.01856, in Hispanics.

A26 (96%) and A30 (96%) were well typed and confirmed as A\*26:01 (42%) and A\*30:01 (42%). A\*26:01:01 and B\*30:01:01 were each assigned by 5 labs. B38 (96%) and B49 (93%) were the B-locus types. B\*38:01 was reported by 48%, with 5 labs assigning B\*38:01:01. B\*49:01 was assigned by 45%.

**Cell 1530.** The consensus type for this Filipino sample is A\*02:07(A2)-A\*24:10(A24)-B\*18:02(B18)-B\*46:01(B46)-C\*01:02(Cw1)-C\*07:04(Cw7). The likely haplotypes in this cell are A\*02:07-B\*46:01-C\*01:02 and A\*24:10-B\*18:02-C\*07:04, with respective frequencies of 0.03251 and 0.00114, in Asians. A\*02:07-B\*46:01-C\*01:02 is the second most frequently observed haplotype in Asian populations.

A24 was detected by 96%, with 9 labs assigning A2403 and 1 lab assigning A24V. A\*24:10 (48%) was assigned by DNA, with 5 labs assigning A\*24:10:01. This is the first time this variant of A24 was typed by both serology and DNA in the Cell Exchange. A2 was reported in complete consensus and confirmed as A\*02:07 (39%). A\*02:07:01 was assigned by 5 labs.

**Cell 1531.** The consensus type for this Hispanic sample is A\*33:01(A33)-A\*68:03(A68)-B\*14:02(B65)-B\*40:02(61)-C\*03:05(Cw3)-C\*08:02(Cw8). The likely haplotypes in this cell are A\*68:03-B\*40:02-C\*03:05 and A\*33:01-B\*14:02-C\*08:02, with respective frequencies of 0.00066 and 0.01439, in Hispanics. The B\*40:02-C\*03:05 association in this cell was observed in 4 other previous exchange samples, cells 1061, 1240, 1474, and 1498.

Interestingly, the assignment of B61 was relatively low in this sample,

with only 52% of labs assigning B61 as the B40 split. B40 was reported by 32%, with another 12% assigning B60. The assignment of B\*40:02 (B\*40:02:01) (48%) by DNA, confirmed the presence of B61. B14 was detected in complete consensus as the second B-locus type, with 68% of labs reporting B65. B\*14:02 was assigned by 53%, with 5 labs assigning B\*14:02:01.

The C-locus types were Cw3 (60%) and Cw8 (52%), confirmed as C\*03:05 (62%) and C\*08:02 (41%). C\*03:05 was also observed in cells 1061, 1474, and 1498, all from Hispanic donors.

**Cell 1532.** The consensus type for this Filipino sample is A\*11:01(A11)-B\*13:01(B13)-B\*56:04(B56)-C\*01:02(Cw1)-C\*04:06. The likely associations in this cell are B\*56:04-C\*01:02 and B\*13:01-C\*04:06, each with a frequency of 0.00114, in Asians. The B\*13:01-C\*04:06 associations in this cell was observed in 2 other previous exchange samples, cells 1452 and 1319 (same as 1261, 1005), both from Filipino donors.

This sample was previously typed as cell 1475 in 2012, as noted by Claas, Kvam, Lopez-Cepero, and Rees. In this present retyping, B56 was well typed by 92%, an increase from a detection level of 84% in 2012. The assignment of B\*56:04 also increased from 46% to 53% in this present typing. This rare B22 variant has been observed in only 1 other exchange sample, cell 1394 (same as 1026, 1075, 1230, 1260), also from a Filipino donor. B13 was assigned in complete consensus as the second B-locus type and confirmed as B\*13:01 (50%).

Another variant detected in this cell was Cw4X6. Labs were split in their assignments of Cw4 and Cw6, with 28% assigning Cw4 and 24% assigning Cw6. Several labs noted this cell as being reactive to multi-specific sera containing Cw4 and Cw6. The presence of this variant was confirmed by DNA, as C\*04:06 was reported by 48%.

**Table 7. Summary of the 383<sup>rd</sup> Cell Exchange (Cell #1529-1532)**

DNA Typing							
Cell 1529		Cell 1530		Cell 1531		Cell 1532	
<u>31 labs</u>	% (n)	<u>31 labs</u>	% (n)	<u>30 labs</u>	% (n)	<u>30 labs</u>	% (n)
A*26:01:01	16(5)	A*02:07:01	16(5)	A*33:01:01	13(4)	A*11:01:01	10(3)
A*26:01	26(8)	A*02:07	23(7)	A*33:01	30(9)	A*11:01	37(11)
A*26:01+	10(3)	A*02:07+	13(4)	A*33:01+	10(3)	A*11:01+	10(3)
A*26	48(15)	A*02	48(15)	A*33	47(14)	A*11	43(13)
A*30:01:01	16(5)	A*24:10:01	16(5)	A*68:03:01	13(4)		
A*30:01	26(8)	A*24:10	32(10)	A*68:03	50(15)		
A*30:01+	10(3)	A*24:10/210	10(3)	A*68	37(11)		
A*30	48(15)	A*24	42(13)				
<u>31 labs</u>	% (n)	<u>31 labs</u>	% (n)	<u>30 labs</u>	% (n)	<u>30 labs</u>	% (n)
B*38:01:01	16(5)	B*18:02	45(14)	B*14:02:01	17(5)	B*13:01:01	3 (1)
B*38:01	32(10)	B*18:01+	3 (1)	B*14:02	36(11)	B*13:01	47(14)
B*38:01+	3 (1)	B*18	52(16)	B*14:02+	10(3)	B*13:11	3 (1)
B*38	49(15)			B*14(B65)	13(4)	B*13:01+	3 (1)
				B*14	23(7)	B*13	43(13)
B*49:01:01G	3 (1)	B*46:01:01	13(4)	B*40:02:01	17(5)	B*56:04	53(16)
B*49:01	42(13)	B*46:01	26(8)	B*40:02	31(9)	B*56:04+	10(3)
B*49:01+	7 (2)	B*46:01+	10(3)	B*40:02+	17(5)	B*56	37(11)
B*49	48(15)	B*46	51(16)	B*40(B61)	17(5)		
				B*40	17(5)		
<u>30 labs</u>	% (n)	<u>30 labs</u>	% (n)	<u>29 labs</u>	% (n)	<u>29 labs</u>	% (n)
C*07:01:01G	3 (1)	C*01:02:01	7 (2)	C*03:05	62(18)	C*01:02:01	7 (2)
C*07:01	27(8)	C*01:02:01G	3 (1)	C*03:05+	10(3)	C*01:02	27(8)
C*07:01+	23(7)	C*01:02	20(6)	C*03:04+	3 (1)	C*01:02+	21(6)
C*07	47(14)	C*01:02+	17(5)	C*03(Cw10)	3 (1)	C*01	45(13)
		C*01	53(16)	C*03	21(6)		
C*12:03	40(12)	C*07:04:01	10(3)	C*08:02:01	14(4)	C*04:06	48(14)
C*12:03+	13(4)	C*07:04:01G	3 (1)	C*08:02	27(8)	C*04:06+	14(4)
C*12	47(14)	C*07:04	20(6)	C*08:02+	14(4)	C*04	38(11)
		C*07:04+	20(6)	C*08	45(13)		
		C*07	47(14)				

**Table 8: Summary of the 383rd Cell Exchange (Cell #1529-1532)**

**Serological Typing**

(Hispanic) <b>Cell 1529</b>	
(27 Samples Typed)	
A26	96.3%
A10	3.7%
	[100.0%]
A30	96.3%
A19	3.7%
	[100.0%]
B38	96.3%
	[96.3%]
B49	92.6%
B21	7.4%
	[100.0%]
CW7	51.9%
BW4	85.2%
BW6	3.7%
<b>Others Found</b>	
CW12	3.7%
CW17	3.7%
A34	3.7%
CW6	3.7%
B39	3.7%

(Filipino) <b>Cell 1530</b>	
(27 Samples Typed)	
A2	100.0%
	[100.0%]
A24	59.0%
A2403	33.3%
A24V	3.7%
A9	3.7%
	[100%]
B18	100.0%
B46	100.0%
CW1	55.6%
CW7	51.9%
BW6	81.5%
<b>Others Found</b>	
CW3	7.4%
BW4	3.7%

(Hispanic) <b>Cell 1531</b>	
(25 Samples Typed)	
A33	100.0%
	[100.0%]
A68	68.0%
A28	32.0%
	[100.0%]
B65	68.0%
B14	32.0%
	[100.0%]
B40	32.0%
B60	12.0%
B61	52.0%
	[100.0%]
CW3	60.0%
	[60.0%]
CW8	52.0%
BW6	84.0%
<b>Others Found</b>	
B48	4.0%

(Filipino) <b>Cell 1532</b>	
(25 Samples Typed)	
A11	92.0%
A11.1	4.0%
A1101	4.0%
	[100.0%]
B13	100.0%
B56	92.0%
B22	8.0%
	[100.0%]
CW1	56.0%
CW4	28.0%
CW6	24.0%
	[52.0%]
BW6	80.0%
BW4	80.0%
<b>Others Found</b>	

Table 9. Individual laboratory results for Cell #1529 by DNA								
Center	Investigator	HLA-A		HLA-B		HLA-C		Method
16	Askar,Medhat	*26:01:01	*30:01:01	*38:01:01	*49:01	*07:01	*12:03	RSSO,SBT,SSP
774	Cecka,J.Michael	*26	*30	*38	*49	*07	*12	SSP
8070	Chang,Uckjin	*26	*30	*38	*49	*07	*12	SSP
4492	Charron,D.	*26	*30	*38	*49	*07	*12	
798	Claas,F.H.J.	*26:01:01	*30:01:01	*38:01:01	*49:01	*07:01/343	*12:03	SBT
3632	Colombe,Beth	*26:01	*30:01	*38:01	*49:01	*07:01	*12:03	SSO,SSP
779	Daniel,Claud	*26	*30	*38	*49	*07	*12	PCR-SSP,SSO
3766	Dunn,Paul	*26	*30	*38	*49	*07	*12	SSO
5214	Eckels/CPMC	*26	*30	*38	*49	*07	*12	SSO
762	Fischer,Gottfried	*26	*30	*38	*49	*07	*12	SSO,SSP
4079	Fort,Marylise	*26	*30	*38	*49	*07	*12	SSP
810	Hamdi,Nuha	*26:01/10/15	*30:01/15/18	*38:01	*49:01	*07:01/05/06	*12:03/06/07	SSO
3808	Hogan,Patrick	*26:01	*30:01	*38:01	*49:01	*07:01/06/18	*12:03	
771	Israel,Shoshana	*26:01	*30:01	*38:01	*49:01	*07:01	*12:03	SBT
9003	Israel_LR	*26	*30	*38	*49	*07	*12	
725	Lardy,N.M.	*26	*30	*38	*49	*07	*12	SSO
745	Latham, Katy	*26:01:01	*30:01:01	*38:01:01	*49:01	*07:01	*12:03	SSO,SSP,SBT
278	Lee,Jar-How	*26:01/77/80/82/85/98	*30:01/73N/78N	*38:01	*49:01/27	*07:01/103/153+	*12:03/23/100+	
6649	Lim,Young Ae	*26	*30	*38	*49			
731	Loewenthal,R	*26:01:01	*30:01:01	*38:01:01	*49:01	*07:01	*12:03	SBT,SSO
759	Lopez-Cepero	*26:01/10/15/17/23+	*30:01/15/18/19/23+	*38:01/09/13/14+	*49:01/06/12/13/14+	*07:01/02/05/06+	*12:03/06/07/12+	RSSO
54	Pancoska,Carol	*26	*30	*38	*49	*07	*12	RSSOP
8001	Rao,Prakash	*26	*30	*38	*49	*07	*12	RSSO,SSP
3625	Rees,Tracey	*26:01	*30:01	*38:01	*49:01	*07:01	*12:03	SBT
1160	Rosen-Bronson	*26:01	*30:01	*38:01	*49:01	*07:01	*12:03	SSO,SSP,SBT
793	Rubocki,Ronald	*26	*30	*38	*49	*07	*12	SSP
4251	Schiller,Jennifer	*26:01	*30:01	*38:01	*49:01	*07:01:01G	*12:03	PCR-RSSO,SBT
3545	Scornik,Juan C	*26:01	*30:01	*38:01	*49:01	*07:01/06/18/343	*12:03	SSOP,SBT
747	Tiercy,Jean-Marie	*26:01:01	*30:01:01	*38:01:01	*49:01:01G	*07:01/166	*12:03/100	SSO,SSP,SBT
5462	Turner,E.V.	*26:01	*30:01	*38:01	*49:01	*07:01	*12:03	SBT,SSO
3186	Watson,Narelle	*26	*30	*38	*49	*07	*12	SSO

Table 10. Individual laboratory results for Cell #1530 by DNA								
Center	Investigator	HLA-A		HLA-B		HLA-C		Method
16	Askar,Medhat	*02:07:01	*24:10:01	*18:02	*46:01:01	*01:02:01	*07:04:01	RSSO,SBT,SSP
774	Cecka,J.Michael	*02:07/219/335/426+	*24:10	*18	*46	*01	*07	SSP
8070	Chang,Uckjin	*02	*24	*18	*46	*01	*07	SSP
4492	Charron,D.	*02	*24	*18	*46	*01	*07	
798	Claas,F.H.J.	*02:07:01	*24:10:01	*18:02	*46:01:01	*01:02:01	*07:04:01	SBT
3632	Colombe,Beth	*02:07	*24:10	*18:02	*46:01	*01:02	*07:04	SSO,SSP
779	Daniel,Claud	*02	*24	*18	*46	*01	*07	PCR-SSP,SSO
3766	Dunn,Paul	*02	*24:10/210	*18	*46	*01	*07	SSO
5214	Eckels/CPMC	*02	*24	*18	*46	*01	*07	SSO
762	Fischer,Gottfried	*02	*24	*18	*46	*01	*07	SSO,SSP
4079	Fort,Marylise	*02	*24	*18	*46	*01	*07	SSP
810	Hamdi,Nuha	*02:01/01L/01Q	*24:10/210	*18:02	*46:01/15N/24	*01:02/07/11	*07:04/11/12	SSO
3808	Hogan,Patrick	*02	*24	*18	*46	*01	*07:04+	
771	Israel,Shoshana	*02:07	*24:10	*18:02	*46:01	*01:02	*07:04	SBT
9003	Israel_LR	*02	*24	*18	*46	*01	*07	
725	Lardy,N.M.	*02	*24	*18	*46	*01	*07	SSO
745	Latham, Katy	*02:07:01	*24:10:01	*18:02	*46:01	*01	*07:04/329N	SSO,SSP,SBT
278	Lee,Jar-How	*02:07/426/432+	*24:10	*18:02	*46:01/24/34/38/39+	*01:02/25/40/44/82+	*07:04/324/329N	
6649	Lim,Young Ae	*02	*24	*18	*46			
731	Loewenthal,R	*02:07:01	*24:10:01	*18:02	*46:01:01	*01:02	*07:04	SBT,SSO
759	Lopez-Cepero	*02:01/07/09/15N+	*24:10/210	*18:01/02/05/08+	*46:01/02/15N/16+	*01:02/07/11/15/18+	*07:04/11/12/63/142+	RSSO
54	Pancoska,Carol	*02	*24:10	*18	*46	*01	*07	RSSOP
8001	Rao,Prakash	*02	*24	*18	*46	*01	*07	RSSO,SSP
3625	Rees,Tracey	*02:07	*24:10	*18:02	*46:01	*01:02	*07:04	SBT
1160	Rosen-Bronson	*02:07	*24:10	*18:02	*46:01	*01:02/60/85	*07:04/11/12	SSO,SSP,SBT
793	Rubocki,Ronald	*02	*24	*18	*46	*01	*07	SSP
4251	Schiller,Jennifer	*02:07	*24:10	*18:02	*46:01	*01:02	*07:04:01G	PCR-RSSO,SBT
3545	Scornik,Juan C	*02:07	*24:10	*18:02	*46:01	*01:02/85	*07:04/11	SSOP,SBT
747	Tiercy,Jean-Marie	*02:07:01	*24:10:01	*18:02	*46:01:01	*01:02:01G	*07:04:01	SSO,SSP,SBT
5462	Turner,E.V.	*02:07	*24:10	*18:02	*46:01	*01:02	*07:04	SBT,SSO
3186	Watson,Narelle	*02	*24	*18	*46	*01	*07	SSO

Table 11. Individual laboratory results for Cell #1531 by DNA								
Center	Investigator	HLA-A		HLA-B		HLA-C		Method
16	Askar,Medhat	*33:01:01	*68:03:01	*14:02:01	*40:02:01	*03:05	*08:02:01	RSSO,SBT,SSP
774	Cecka,J.Michael	*33	*68	*14	*40	*03	*08	SSP
8070	Chang,Uckjin	*33	*68	*14	*40	*03	*08	SSP
4492	Charron,D.	*33	*68	*14	*40	*03:02/04/05/06/09/14	*08	
798	Claas,F.H.J.	*33:01:01	*68:03:01	*14:02:01	*40:02:01	*03:05	*08:02:01	SBT
3632	Colombe,Beth	*33:01	*68:03	*14:02	*40:02	*03:05	*08:02	SSO,SSP
779	Daniel,Claud	*33	*68:03	*14 (B65)	*40 (B61)	*03:05	*08	PCR-SSP,SSO
3766	Dunn,Paul	*33	*68:03	*14	*40:02+	*03:05+	*08	SSO
5214	Eckels/CPMC	*33	*68:03	*14 (B65)	*40 (B61)	*03:05	*08	SSO
762	Fischer,Gottfried	*33:01	*68:03	*14:02	*40:02	*03:05	*08:02	SSO,SSP,SBT
4079	Fort,Marylise	*33:01/32/64/68	*68:03	*14:02	*40:02	*03:05	*08:02	SSO,SSP
810	Hamdi,Nuha	*33:01/03/03Q	*68:03	*14:02	*40:02/56/97	*03:05	*08:02/05/17	SSO
3808	Hogan,Patrick	*33	*68	*14:02	*40:02+	*03:04+	*08	
771	Israel,Shoshana	*33:01	*68:03	*14:02	*40:02	*03:05	*08:02	SBT
9003	Israel_LR	*33	*68	*14	*40	*03	*08	
725	Lardy,N.M.	*33	*68	*14	*40	*03	*08	SSO
745	Latham, Katy	*33:01:01	*68:03:01	*14:02:01	*40:02:01	*03:05	*08:02:01	SSO,SSP,SBT
278	Lee,Jar-How	*33:01	*68:03	*14:02	*40:02/56/97/144N+	*03:05	*08:02/34/52N/75/90	
6649	Lim,Young Ae	*33	*68	*14	*40 (B61)			
731	Loewenthal,R	*33:01:01	*68:03:01	*14:02:01	*40:02:01	*03:05	*08:02:01	SBT,SSO
759	Lopez-Cepero	*33:01/03/04/05/06+	*68:03	*14:02/09/16/17/18+	*40:02/35/50/56/57+	*03:05/25/27/35/143+	*08:02/05/17/32/34+	RSSO
54	Pancoska,Carol	*33	*68	*14 (B65)	*40 (B61)	*03	*08	RSSOP
8001	Rao,Prakash	*33	*68	*14:02/09	*40:02/50/90/94	*03:05	*08	RSSO,SSP
3625	Rees,Tracey	*33:01	*68:03	*14:02	*40:02	*03:05	*08:02/75	SBT
1160	Rosen-Bronson	*33:01	*68:03	*14:02/18	*40:02/50	*03:05	*08:02	SSO,SSP,SBT
793	Rubocki,Ronald	*33	*68	*14 (B65)	*40 (B61)	*03 (Cw10)	*08	SSP
4251	Schiller,Jennifer	*33:01	*68:03	*14:02	*40:02	*03:05	*08:02	PCR-RSSO,SBT
3545	Scornik,Juan C	*33:01	*68:03	*14:02	*40:02	*03:05	*08:02	SSOP,SBT
747	Tiercy,Jean-Marie	NT						SSO,SSP,SBT
5462	Turner,E.V.	*33:01	*68:03	*14:02	*40:02	*03:05	*08:02	SBT,SSO
3186	Watson,Narelle	*33	*68	*14:02:01	*40:02:01	*03	*08	SSO,SBT-B only

Table 12. Individual laboratory results for Cell #1532 by DNA								
Center	Investigator	HLA-A		HLA-B		HLA-C		Method
16	Askar,Medhat	*11:01		*13:01	*56:04	*01:02:01	*04:06	RSSO,SBT,SSP
774	Cecka,J.Michael	*11		*13	*56	*01	*04:06	SSP
8070	Chang,Uckjin	*11		*13	*56	*01	*04	SSP
4492	Charron,D.	*11		*13	*56	*01	*04	
798	Claas,F.H.J.	*11:01:01		*13:01:01	*56:04	*01:02:01	*04:06	SBT
3632	Colombe,Beth	*11:01		*13:01	*56:04	*01:02	*04:06	SSO,SSP
779	Daniel,Claud	*11		*13	*56:02/04	*01	*04	PCR-SSP,SSO
3766	Dunn,Paul	*11		*13	*56:02/04	*01	*04:03/06/107	SSO
5214	Eckels/CPMC	*11		*13	*56	*01	*04	SSO
762	Fischer,Gottfried	*11:01		*13:01	*56:04	*01:02/85	*04:06	SSO,SSP,SBT
4079	Fort,Marylise	*11:01/126/163		*13:01	*56:04	*01:02	*04:06	SSO,SSP
810	Hamdi,Nuha	*11:01/02/03	*11:01/02/03	*13:11	*56:04	*01:02/03/07	*04:03/06/107	SSO
3808	Hogan,Patrick	*11:01		*13:01	*56:04	*01	*04	
771	Israel,Shoshana	*11:01		*13:01	*56:04	*01:02	*04:06	SBT
9003	Israel_LR	*11		*13	*56	*01	*04	
725	Lardy,N.M.	*11		*13	*56	*01	*04	SSO
745	Latham,Katy	*11:01:01		*13:01	*56:04	*01:02/22	*04:03/06	SSO,SSP,SBT
278	Lee,Jar-How	*11:01		*13:01	*56:04	*01:02	*04:06	
6649	Lim,Young Ae	*11		*13	*56			
731	Loewenthal,R	*11:01:01		*13:01	*56:04	*01:02	*04:06	SBT,SSO
759	Lopez-Cepero	*11:01/02/03/05/07+		*13:01/10/11/17/22+	*56:02/04	*01:02/03/07/11/15+	*04:06/03/107	RSSO
54	Pancoska,Carol	*11		*13	*56	*01	*04	RSSOP
8001	Rao,Prakash	*11		*13	*56	*01	*04	RSSO,SSP
3625	Rees,Tracey	*11:01		*13:01	*56:04	*01:02	*04:06	SBT
1160	Rosen-Bronson	*11:01		*13:01	*56:04	*01:02/85	*04:06	SSO,SSP,SBT
793	Rubocki,Ronald	*11		*13	*56	*01	*04	SSP
4251	Schiller,Jennifer	*11:01	*11:01	*13:01	*56:04	*01:02	*04:06	PCR-RSSO,SBT
3545	Scornik,Juan C	*11:01		*13:01	*56:04	*01:02/85	*04:06	SSOP,SBT
747	Tiercy,Jean-Marie	NT						SSO,SSP,SBT
5462	Turner,E.V.	*11:01		*13:01	*56:04	*01:02	*04:06	SBT,SSO
3186	Watson,Narelle	*11		*13	*56	*01	*04	SSO



**Table 13. Individual laboratory results for Cell #1529-1532 by Serology**

Investigator	Days Old	Cell No 1529 (Hispanic)									Cell No 1530 (Filipino)								Cell No 1531 (Hispanic)								Cell No 1532 (Filipino)										
		Viab %	A26	A30	B38	B49	Cw7	Bw4	Bw6	OTHERS	Viab %	A2	A24	B18	B46	Cw1	Cw7	Bw6	OTHERS	Viab %	A33	A68	B65	B61	Cw3	Cw8	Bw6	OTHERS	Viab %	A11	B13	B56	Cw1	Cw4	Bw6	Bw4	OTHERS
Alonso, Anton																																					
Alvarez, Carr		90	+	+	+	+	+			90	+	+	+	+			+		90	+	+	B14	B60			+		90	+	+	+			+	+		
Askar, Medhat	2	95	+	+	+	+	+	+		95	+	A24V	+	+	+	+	+		95	+	+	+	B40	+	+	+		95	+	+	+	+	w6	+	+		
Cecka, J. Mic		95	+	+	+	+	+	+		95	+	+	+	+			+		95	+	+	+	+			+		95	+	+	+			+	+		
Charron, Dorni		98	+	+	+	+				98	+	+	+	+					98	+	+	B14	B40					98	+	+	+						
Claas, F.H.J.	6	90	+	+	+	+		+		90	+	A2403	+	+	+		+		90	+	A28	B14	+	+		+	90	+	+	+	+	+	+	+	+		
Dunn, Paul	7	90	+	+	+	+		+		92	+	+	+	+			+		92	+	+	+	B60			+	94	+	+	+			+	+			
Enczmann, J		95	+	+	+	+				90	+	A2403	+	+					85	+	+	+	+				85	+	+	+							
Esteves Kondo	2	98	+	+	+	+	+	+		98	+	+	+	+	+	+	+		98	+	+	+	+	+	+	+	98	+	+	+	+	+	+	+	+		
Fort, Marylis	3	98	+	+	+	+	+	+		98	+	+	+	+			+																				
Gideoni, Osna																																					
Hahn, Amy B.		100	+	+	+	+	+	+		Cw6	100	+	A2403	+	+	+	+	+	100	+	+	+	B40	+	+	+	B14	100	A1101	+	+	+	w6				
Hesse, Kissel																																					
Hogan, Patric	7	60	+	+	+	+	+	+		60	+	+	+	+	+	+	+		60	+	+	+	+	+	+		60	+	+	+	+	+	+	+	+		
Israel, Shosh																																					
Klein, Tirza																																					
Kvam, Vonnett	3	97	+	+	+	+	+	+		95	+	A2403	+	+	+	+	+		93	+	A28	+	B60	+	+	+		95	+	+	+	+	w6	+	+		
Latham, Katy		90	+	+	+	+				95	+	+	+	+					90	+	+	B14	+				90	+	+	+							
Loewenthal MD		80	+	+	+	+	+	+		90	+	A2403	+	+	+	+	+		80	+	A28	+	B40	+		+	80	+	+	+	+		+	+			
Mah, Helen	2	98	+	+	+	+	+	+		Cw12	98	+	A2403	+	+	+	+	+	98	+	+	+	+	+	+	+	98	+	+	+	+	+	+	+	+	+	
Meyer, Pieter		95	A10	+	+	+	+				80	+	+	+	+	+		Cw3	90	+	+	+	B40	+	+		70	+	+	+	+	w6					
Norin, Allen		99	+	+	+	+	+	+			99	+	+	+	+	+	+		99	+	+	+	+	+	+	+	99	+	+	+			+	+			
Pancoska, Car	2	98	+	+	+	+	+	+			98	+	A2403	+	+	+	+	+	97	+	+	+	+	+	+	+	97	+	+	+	+	w6	+	+			
Permpikul, Ve	6	90	+	+		+		+		B39	90	+	+	+	+		+		90	+	A28	B14	+			+	90	A11.1	+	+			+	+			
Pollack, Mari																																					
Rees, Tracey	3	90	+	+	+	+	+	+		90	+	A2403	+	+	+	+	+		90	+	+	+	+	+	+	+	90	+	+	+	+	+	+	+	+		
Renac, Virgin		99	+	+	+	B21		+		99	+	+	+	+		+			99	+	A28	B14	B40			+	99	+	+	B22			+	+			
Rosen-Bronson		95	+	+	+	+	+	+		95	+	+	+	+	+	+	+		95	+	+	+	+	+	+	+	95	+	+	+	+	+	+	+	+		
Rubocki, Rona	2	98	+	+	+	+	+	+		98	+	+	+	+	+	+	+		98	+	A28	+	B40	+	+	+	98	+	+	+	+	+	+	+	+		
Shai, Isaac	8	90	+	+	+	+	+	+		+	A34>	86	+	+	+	+	+	+	Cw3	90	+	A28	B14	B60	+	+	+	88	+	+	+	+	+	+	+	Cw6	
Tiercy, Jean-	6	90	+	+	+	+		+			90	+	A2403	+	+			Bw4																			
Varnavidou-Ni																																					
Vidan-Jeras,	6	95	+	+	+	+	+	+		95	+	+	+	+	+	+	+		100	+	+	+	+	+	+	+	95	+	+	+			+	+			
Watson, Narel	7	90	+	A19	+	B21		+		85	+	A9	+	+		+			90	+	A28	B14	B40			+	90	+	+	B22			+	+			

# Serum Exchange #541

The results for Serum Exchange #541 (sera 1157-1160), are summarized in Tables 14-19 and individual laboratory results by method are listed in Tables

20-30. Sera strongly positive to 1C and 10C specificities were examined in this study.

1157	method	#labs	A3	A30	A33	A25	A26	A31	A32	A34	A11	A66	A29	A68	A74	A1	A69	A24	A36	B18	A43	A80	Cw12	Cw17	Cw6	A6601	A6602	A1101	A1102	A23	A2403	A2
	NIH-Std	7	100	14	14	14	14			14	86				14																	14
	NIH-Ext	2	100	50	50	50	50	50	50	50		50																				
	AHG	4	75	75	75	50	50	75	50	50	75		75	50	75																	
	Luminex	27	100	100	100	96	96	100	100	100	85	74	96	100	100	78	100	85	74	93	89	78	67	56	48	37	37	22	22	37	22	
	ELISA	2	50	100	50	100	50	50	100	50	100	50	100	50		50	50	50	50													
	Flow	1	no consensus																													
	C1q	1	no consensus																													
	Other	3	67	33		33		33	33	33	33	33	33	33		33																

1157	method	#labs	DR15			
	NIH-Std	5	20			
	Luminex	23	no antigens assigned			
	Other	2	no antigens assigned			

**Sample 1157** was found to be strongly positive to A3. Additional anti-A11, A25, A26, A30, and A33 reactivity was detected by various methods. Positivity to other 1C and 10C specificities was also reported AHG, Luminex, and Flow. Lumimex reported additional reactivity to C-locus antigens (Cw6, Cw12, Cw17). DR15 was reported by 1 lab using NIH-Std.

1158	method	#labs	A3	A2	A31	A68	A33	A30	A29	B61	A74	B60	B27	A69	A32	A25	A80	A36	B13	B7	B65	B47	B81	B42	A34	B48	A32	A66	B67	B55	A11	B56	B73	Cw6	Cw7	A26	A28	A24	
	NIH-Std	7	86	43	50	50			14	14		14																									14	14	14
	NIH-Ext	2	100	50	50	50																																	
	AHG	4	100	100	75	50	100	75	100	50	75	50	50		50																								
	Luminex	27	100	100	100	100	100	100	100	93	100	93	96	100		70	67	63	81	100		93	85	81	78	78	78	74	70	70	63	48	48	93	71				
	ELISA	2	100	100	50	50	50	100	100	100	100				50	50	100	50	50	50		100																	
	Flow	1	no consensus																																				
	C1q	1	no consensus																																				
	Other	2	50	50	50	50	50	50																															

For **Sample 1158**, strong reactivity to A3 was reported by multiple methods. Reactivity to A2, 1C, 10C, and 7C specificities was also detected by various methods. ELISA reported additional positivity to B65, and Luminex reported additional reactivity to Cw6 and Cw7. Anti-DR7 and -DR15 reactivi-

ty was reported by NIH-Standard, Luminex, and 1 lab reporting by Luminex PRA. Luminex and Luminex PRA also detected reactivity to DR9, DR16, and DQ2. Additional reactivity to a number of DP antigens was reported by Luminex.

1158	method	#labs	DR7	DR15	DR9	DR16	DQ2	DR12	DP14	DP11	DP17	DPw5	DR103	DR1	DP15	DP9	DQ5	DP10	DP13	DR51	DPw1	DPw3	DPw6	DP18	DQ9	DQ4	DQ7
	NIH-Std	5	20	20										20													
	Luminex	23	87	73	87	87	87	73	65	61	61	61	61		56	56	56	52	44	44	35	35	35	30	30	26	26
	Other	2	50	50	50	50	50																				

1159	method	#labs	A31	A30	A29	A74	A33	A32	A34	A25	A26	A66	B8	A43	A23	A6601	A6602	A1	A36	B44	B63	Cw15	Cw4
	NIH-Std	5	80	60	20	20							20										
	NIH-Ext	2	100	100				50	50														
	AHG	4	100	100	50	50																	
	Luminex	26	100	100	100	96	96	85	100	77	73	69	19	69	50	38	38						19
	ELISA	2	100	100	100	100	50	50	50	50	100	50						50	50	50	50	50	
	Flow	1	no consensus																				
	C1q	1	no consensus																				
	Other	3	33	33	33	33	33	33	33	33	33	33											

**Sample 1159** was reported to be strongly positive to A30 and A31 by all methods. Reactivity a number of 10C specificities was reported by various methods. Additional reactivity to A1, A36, B44, B63, and Cw15 was reported by ELISA. Anti-DR52 reactivity was reported by NIH-Standard, Luminex and PRA. Additional reactivity to DQ7 and DR8, DR11, DR12, DR13, DR14, DR17, and DR18 was reported by Luminex and Luminex PRA. Luminex also detected reactivity to a number of DP antigens.

1159	method	#labs	DR52	DR8	DR11	DR12	DR13	DR14	DR17	DR18	DQ7	DR7	DR9	DP18	DPW2	DPW4	DP15	DP11	DP17	DQ2	DPw3	DPw1	DP13	DPw6
	NIH-Std	4	25																					
	Luminex	22	77	86	86	86	86	86	77	77	77	86	86	73	68	68	64	55	55	45	41	32	27	27
	Other	2	50	50	50	50	50	50	50	50	50													

For **Sample 1160**, strong reactivity to A34 was reported by AHG, Luminex, and ELISA. Additional reactivity to other 10C specificities was reported by various methods. Luminex also reported reactivity to a number of 7C and 8C specificities. Anti-DR52 reactivity was reported by NIH-Standard, Luminex, and Luminex PRA. Additional reactivity to DQ4 and a number of DR antigens was reported by Luminex and Luminex PRA. Luminex also reported positivity to DP antigens (DPw1, DPw4, DPw5, DP11, DP13, DP15).

1160	method	#labs	A34	A25	A26	A66	A33	A68	A69	A31	A29	B8	B44	B54	B47	B49	A28	A25	B38	B39	Cw7	B18	
	NIH-Std	4	25	25	25	25	25					25	25				50						
	NIH-Ext	2	50					50															
	AHG	4	75	75	75	50	75	50															
	Luminex	26	100	96	100	73	100	100	100	77	58	69	58	46	23	23		88	61	77	73	73	
	ELISA	2	100	50	100	50	100	100	50	50	50		50	50	50								
	Flow	1	no consensus																				
	C1q	1	no consensus																				
	Other	3	33	33	33	33	33	33	33														

  

1160	method	#labs	A3	B45	A30	B63	B41	B64	B65	A74	B59	A6601	A6602	Cw10	B50	B60	B61	A23	B75	B81	Cw16	A10
	NIH-Std	4																				25
	NIH-Ext	2																				
	AHG	4																				
	Luminex	26	62	58	58	54	50	50	50	46	46	35	35	31	23	23	23					
	ELISA	2																50	50	50	50	
	Flow	1																				
	C1q	1																				
	Other	3																				

1160	method	#labs	DR52	DR4	DR8	DR11	DR12	DR13	DR14	DR15	DR16	DR17	DR18	DR103	DQ4	DPw1	DP11	DR51	DP13	DP15	DPw4	DPw5	DQ2	DQ7	DQ9
	NIH-Std	4	50																						
	Luminex	21	81	90	90	90	90	90	86	76	90	81	81	81	90	67	62	62	57	52	52	52	38	38	29
	Other	2	50	50	50	50	50	50	50	50	50	50	50	50	50										

**Table 14. Summary of the 541st Serum Exchange (Serum #1157-1160) by NIH-Standard and NIH-Extended**

<b>Method: NIH-Standard</b>											
<b>*** Serum 1157 ***</b>			<b>*** Serum 1158 ***</b>			<b>*** Serum 1159 ***</b>			<b>*** Serum 1160 ***</b>		
7 typing Labs			7 typing Labs			5 typing Labs			4 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A3	100%	94%	A3	86%	70%	A31	80%	85%	A28	50%	100%
A11	86%	68%	A2	43%	100%	A30	60%	60%	A10	25%	100%
A2	14%	100%	A26	14%	100%	A29	20%	100%	A25	25%	100%
A25	14%	100%	A28	14%	100%	A74	20%	100%	A26	25%	100%
A30	14%	100%	A29	14%	100%	B8	20%	100%	A33	25%	100%
A33	14%	100%	B60	14%	100%				A34	25%	100%
A34	14%	100%	B61	14%	100%				A66	25%	100%
A74	14%	100%	A24	14%	50%				B8	25%	100%
A26	14%	50%							B44	25%	19%

<b>Method: NIH-Extended</b>											
<b>*** Serum 1157 ***</b>			<b>*** Serum 1158 ***</b>			<b>*** Serum 1159 ***</b>			<b>*** Serum 1160 ***</b>		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A3	100%	100%	A3	100%	100%	A30	100%	100%	A34	50%	50%
A31	50%	100%	A31	50%	75%	A31	100%	92%	A68	50%	17%
A66	50%	100%	A68	50%	67%	A34	50%	50%			
A32	50%	88%	A2	50%	62%	A32	50%	38%			
A26	50%	75%									
A30	50%	67%									
A25	50%	50%									
A33	50%	50%									

**Table 15. Summary of the 541st Serum Exchange (Serum #1157-1160) by Antiglobulin and Other**

Method: Antiglobulin											
*** Serum 1157 ***			*** Serum 1158 ***			*** Serum 1159 ***			*** Serum 1160 ***		
4 typing Labs			4 typing Labs			4 typing Labs			4 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A11	75%	100%	A3	100%	100%	A31	100%	100%	A25	75%	100%
A29	75%	100%	A2	100%	81%	A30	100%	60%	A26	75%	100%
A3	75%	100%	A33	100%	73%	A29	50%	100%	A33	75%	100%
A30	75%	100%	A29	75%	100%	A74	50%	25%	A34	75%	100%
A31	75%	100%	A31	75%	100%	A33	50%	20%	A66	50%	100%
A33	75%	100%	A74	75%	100%				A68	50%	100%
A74	75%	100%	A30	75%	78%						
A25	50%	100%	A68	50%	100%						
A26	50%	100%	B27	50%	100%						
A32	50%	100%	B60	50%	100%						
A34	50%	100%	B61	50%	100%						
A68	50%	100%	A32	50%	75%						

Method: Other											
*** Serum 1157 ***			*** Serum 1158 ***			*** Serum 1159 ***			*** Serum 1160 ***		
3 typing Labs			2 typing Labs			3 typing Labs			3 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A3	67%	100%	A2	50%	100%	A25	33%	100%	A25	33%	100%
A1	33%	100%	A3	50%	100%	A26	33%	100%	A26	33%	100%
A11	33%	100%	A30	50%	100%	A29	33%	100%	A33	33%	100%
A25	33%	100%	A31	50%	100%	A30	33%	100%	A34	33%	100%
A29	33%	100%	A33	50%	100%	A31	33%	100%	A66	33%	100%
A30	33%	100%	A68	50%	100%	A32	33%	100%	A68	33%	100%
A31	33%	100%				A33	33%	100%	A69	33%	100%
A32	33%	100%				A34	33%	100%			
A34	33%	100%				A66	33%	100%			
A66	33%	100%				A74	33%	100%			
A68	33%	100%									

**Table 16. Summary of the 541st Serum Exchange (Serum #1157-1160) by Luminex - class I**

<b>*** Serum 1157 ***</b>		
27 typing Labs		
Antigen	Consensus	Inclusion
A3	100%	100%
A30	100%	100%
A31	100%	100%
A32	100%	100%
A33	100%	100%
A34	100%	100%
A68	100%	100%
A69	100%	100%
A74	100%	100%
A25	96%	100%
A26	96%	100%
A29	96%	100%
B18	93%	83%
A43	89%	100%
A11	85%	100%
A24	85%	100%
A80	78%	100%
A1	78%	82%
A36	74%	100%
A66	74%	100%
CW12	67%	100%
CW17	56%	100%
CW6	48%	100%
A23	37%	100%
A6601	37%	100%
A6602	37%	100%
A1101	22%	100%
A1102	22%	100%
A2403	22%	100%

<b>*** Serum 1158 ***</b>		
27 typing Labs		
Antigen	Consensus	Inclusion
A2	100%	100%
A29	100%	100%
A3	100%	100%
A30	100%	100%
A31	100%	100%
A33	100%	100%
A68	100%	100%
A69	100%	100%
A74	100%	100%
B7	100%	100%
B27	96%	100%
B60	93%	100%
B61	93%	88%
CW6	93%	86%
B47	93%	75%
B81	85%	100%
B42	81%	100%
CW7	81%	100%
B13	81%	86%
A34	78%	100%
B48	78%	100%
A32	78%	67%
A66	74%	75%
A25	70%	100%
B67	70%	100%
B55	70%	67%
A80	67%	100%
A36	63%	100%
A11	63%	75%
B56	48%	100%
B73	48%	100%

<b>*** Serum 1159 ***</b>		
26 typing Labs		
Antigen	Consensus	Inclusion
A29	100%	100%
A30	100%	100%
A31	100%	100%
A34	100%	100%
A33	96%	100%
A74	96%	100%
A32	85%	100%
A25	77%	50%
A26	73%	60%
A43	69%	100%
A66	69%	100%
A23	50%	100%
A6601	38%	100%
A6602	38%	100%
B8	19%	100%
CW4	19%	100%

<b>*** Serum 1160 ***</b>		
26 typing Labs		
Antigen	Consensus	Inclusion
A33	100%	100%
A34	100%	100%
A68	100%	100%
A69	100%	100%
A26	96%	100%
A25	88%	100%
B38	61%	80%
A31	77%	100%
B39	77%	100%
A66	73%	100%
CW7	73%	100%
B18	73%	83%
B8	69%	80%
A3	62%	69%
B45	58%	100%
A29	58%	67%
B44	58%	67%
A30	58%	56%
B63	54%	100%
B41	50%	100%
B64	50%	100%
B65	50%	100%
A74	46%	100%
B54	46%	100%
B59	46%	100%
A6601	35%	100%
A6602	35%	100%
CW10	31%	50%
B47	23%	100%
B49	23%	100%
B50	23%	100%
B60	23%	100%
B61	23%	100%

**Table 17. Summary of the 541st Serum Exchange (Serum #1157-1160) by Flow, ELISA, and C1q - class I**

Method: Flow Cytometry											
<b>*** Serum 1157 ***</b>			<b>*** Serum 1158 ***</b>			<b>*** Serum 1159 ***</b>			<b>*** Serum 1160 ***</b>		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
	no consensus			no consensus			no consensus			no consensus	

Method: ELISA											
<b>*** Serum 1157 ***</b>			<b>*** Serum 1158 ***</b>			<b>*** Serum 1159 ***</b>			<b>*** Serum 1160 ***</b>		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A11	100%	100%	A25	100%	100%	A30	100%	83%	A26	100%	100%
A25	100%	100%	A29	100%	100%	A31	100%	67%	A33	100%	100%
A29	100%	100%	A3	100%	100%	A66	100%	67%	A34	100%	100%
A30	100%	100%	A74	100%	100%	A74	100%	67%	A68	100%	100%
A32	100%	100%	B61	100%	100%	A29	100%	60%	A23	50%	100%
A1	50%	100%	B65	100%	100%	A1	50%	100%	A25	50%	100%
A24	50%	100%	A2	100%	89%	A25	50%	100%	A29	50%	100%
A26	50%	100%	A30	100%	60%	A26	50%	100%	A31	50%	100%
A3	50%	100%	A31	50%	100%	A32	50%	100%	A66	50%	100%
A31	50%	100%	A32	50%	100%	A33	50%	100%	A69	50%	100%
A33	50%	100%	A33	50%	100%	A34	50%	100%	B47	50%	100%
A34	50%	100%	A36	50%	100%	A36	50%	100%	B49	50%	100%
A36	50%	100%	A68	50%	100%	B63	50%	100%	B54	50%	100%
A66	50%	100%	A69	50%	100%	B8	50%	100%	B75	50%	100%
A68	50%	100%	A80	50%	100%	CW15	50%	100%	B81	50%	100%
A69	50%	100%	B13	50%	100%	B44	50%	67%	CW16	50%	100%

Method: C1q											
<b>*** Serum 1157 ***</b>			<b>*** Serum 1158 ***</b>			<b>*** Serum 1159 ***</b>			<b>*** Serum 1160 ***</b>		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
	no consensus			no consensus			no consensus			no consensus	

**Table 18. Summary of the 541st Serum Exchange (Serum #1157-1160) by NIH-Standard and Other - class II**

<b>Method: NIH-Standard</b>											
<b>*** Serum 1157 ***</b>			<b>*** Serum 1158 ***</b>			<b>*** Serum 1159 ***</b>			<b>*** Serum 1160 ***</b>		
5 typing Labs			5 typing Labs			4 typing Labs			4 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
DR15	20%	100%	DR1	20%	100%	DR52	25%	100%	DR52	50%	100%
			DR15	20%	100%						
			DR7	20%	100%						

<b>Method: Other</b>											
<b>*** Serum 1157 ***</b>			<b>*** Serum 1158 ***</b>			<b>*** Serum 1159 ***</b>			<b>*** Serum 1160 ***</b>		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no antigens assignd			DQ2	50%	100%	DQ7	50%	100%	DQ4	50%	100%
			DR15	50%	100%	DR11	50%	100%	DR103	50%	100%
			DR16	50%	100%	DR12	50%	100%	DR11	50%	100%
			DR7	50%	100%	DR13	50%	100%	DR12	50%	100%
			DR9	50%	100%	DR14	50%	100%	DR13	50%	100%
						DR17	50%	100%	DR14	50%	100%
						DR18	50%	100%	DR15	50%	100%
						DR52	50%	100%	DR16	50%	100%
						DR8	50%	100%	DR17	50%	100%
									DR18	50%	100%
									DR4	50%	100%
									DR52	50%	100%
									DR8	50%	100%



**Table 19. Summary of the 541st Serum Exchange (Serum #1157-1160) by Luminex - class II**

*** Serum 1157 ***		
23 typing Labs		
Antigen	Consensus	Inclusion
no antigens assigned		

*** Serum 1158 ***		
23 typing Labs		
Antigen	Consensus	Inclusion
DQ2	87%	100%
DR16	87%	100%
DR7	87%	100%
DR9	87%	100%
DR15	73%	100%
DR12	73%	88%
DP14	65%	100%
DP11	61%	100%
DP17	61%	100%
DPW5	61%	100%
DR103	61%	80%
DP15	56%	100%
DP9	56%	100%
DQ5	56%	67%
DP10	52%	100%
DP13	44%	100%
DR51	44%	100%
DPW1	35%	100%
DPW3	35%	100%
DPW6	35%	100%
DP18	30%	100%
DQ9	30%	100%
DQ4	26%	100%
DQ7	26%	100%

*** Serum 1159 ***		
22 typing Labs		
Antigen	Consensus	Inclusion
DR11	86%	100%
DR12	86%	100%
DR13	86%	100%
DR14	86%	100%
DR7	86%	100%
DR8	86%	100%
DR9	86%	100%
DQ7	77%	100%
DR17	77%	100%
DR18	77%	100%
DR52	77%	100%
DP18	73%	100%
DPW2	68%	100%
DPW4	68%	100%
DP15	64%	100%
DP11	55%	100%
DP17	55%	100%
DQ2	45%	100%
DPW3	41%	100%
DPW1	32%	100%
DP13	27%	100%
DPW6	27%	100%

*** Serum 1160 ***		
21 typing Labs		
Antigen	Consensus	Inclusion
DQ4	90%	100%
DR11	90%	100%
DR12	90%	100%
DR13	90%	100%
DR16	90%	100%
DR4	90%	100%
DR8	90%	100%
DR14	86%	100%
DR103	81%	100%
DR17	81%	100%
DR18	81%	100%
DR52	81%	100%
DR15	76%	100%
DPW1	67%	100%
DP11	62%	100%
DR51	62%	100%
DP13	57%	100%
DP15	52%	100%
DPW4	52%	100%
DPW5	52%	100%
DQ2	38%	100%
DQ7	38%	100%
DQ9	29%	100%

**Table 20. Individual laboratory results for Serum #1157-1160 by NIH-Standard and NIH-Extended**

Investigator	**** Serum 1157 ****											**** Serum 1158 ****								**** Serum 1159 ****						**** Serum 1160 ****									Method									
	% POS	A3	A11	A2	A25	A30	A33	A34	A74	A26	Other	%POS	A3	A2	A26	A28	A29	B60	B61	A24	Other	% POS	A31	A30	A29	A74	B8	Other	% POS	A28	A66	A10	A25	A26		A33	A34	B8	B44	Other				
Claas, F.H.J.	46	+	+		+					+		67	+		+			+	+			71						79					+	+									STD	
Fort, Marylise	76	+	+									19	+																														STD	
Hogan, Patric		+	+										+	+									+																				STD	
McCluskey, J		+	+										+							+																								STD
Reed, Elaine	44	+		+								34	+	+								23	+	+				33	+	+				+	+								STD	
Suciu-Foca, N	42	+	+			+	+	+	+			50	+	+		+	+					35	+	+	+	+		20	+		+												STD	
Watson, Nare	27	+	+									29										18	+	+				5											+				STD	

Investigator	**** Serum 1157 ****										**** Serum 1158 ****						**** Serum 1159 ****					**** Serum 1160 ****								Method													
	% POS	A3	A31	A66	A32	A26	A30	A25	A33	Other	% POS	A3	A2	A31	A68	Other	% POS	A31	A30	A34	A32	Other	% POS	A34	A68	Other	Other																
Dunn, Paul	56	+	+	+	+	+	+	+	+		46	+	+	+	+		35	+	+	+	+		13	+	+																		EXT
Lardy, N.M.	26	+									31	+					20	+	+				4																				EXT

**Table 21. Individual laboratory results for Serum #1157-1160 by Antiglobulin and Other**

**** Serum 1157 ****														**** Serum 1158 ****															
Investigator	% POS	A11	A29	A3	A30	A31	A33	A74	A25	A26	A32	A34	A68	Other	% POS	A3	A2	A33	A29	A31	A74	A30	A68	B27	B60	B61	A32	Other	Method
Cecka, J. Michael P	90	+	+	+	+	+	+	+	+	+	+	+	+		85	+	+	+	+	+	+	+	+	+	+	+	+	B48,B13,B7	Antiglobulin
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	A6601		+	+	+	+	+	+	+	+	+	+	+	+		Antiglobulin
Mah, Helen	Multi														+	+	+											Antiglobulin	
Suciu-Foca, Nicole I	45	+	+	+	+	+	+	+				+		A66	70	+	+	+	+	+	+	+					A28	Antiglobulin	

**** Serum 1159 ****														**** Serum 1160 ****															
Investigator	% POS	A31	A30	A29	A74									Other	% POS	A25	A26	A33	A34	A66	A68							Other	Method
Cecka, J. Michael P	18	+	+		+									A33	43	+	+	+	+	+	+								Antiglobulin
Hahn, Amy B. PhD			+	+										B50		+	+	+	+		+							B61,B50,B7 >	Antiglobulin
Mah, Helen		+	+																									B65	Antiglobulin
Suciu-Foca, Nicole I	55	+	+	+	+									A33	50	+	+	+	+	+								A28	Antiglobulin

**** Serum 1157 ****														**** Serum 1158 ****															
Investigator	% POS	A3	A1	A11	A25	A29	A30							Other	% POS	A2	A3	A30	A31	A33	A68							Other	Method
Phelan, Donna	91														96														Other
Reed, Elaine F. PhD	90	+		+	+	+	+							A66,A34,A31,A32 >	98	+	+	+	+	+	+								Other
Rosen-Bronson, Sai		+	+																										Other

**** Serum 1159 ****														**** Serum 1160 ****															
Investigator	% POS	A25	A26	A29	A30	A31								Other	% POS	A25	A26	A33	A34	A66								Other	Method
Phelan, Donna	58														64														Other
Reed, Elaine F. PhD	68	+	+	+	+	+								A66,A34,A32,A33 >	78	+	+	+	+	+								A68,A69	Other
Rosen-Bronson, Sai																													Other

**Table 22. Individual laboratory results for Serum #1157 by Luminex**

		**** Serum 1157 ****																																			
Investigator	% POS	A3	A30	A31	A32	A33	A34	A68	A69	A74	A25	A26	A29	B18	A43	A11	A24	A80	A1	A36	A66	CW12	CW17	CW6	A23	A6601	A6602	A1101	A1102	A2403	Other	Method					
Alvarez, Carretto &	24	+	+	+	+	+	+	+	+	+	+	+	+													+	+	+	+	+			LMX				
Brouard, Tabary/PhD	85	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+			+	+	+		+	+	+	+	+			LMX			
Cecka, J. Michael PhD	87	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+														LMX		
Chen, Dong-Feng		+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+			+	+	+	+	+	+	+	+	+			LMX			
Dunn, Paul	93	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX		
Eckels/CPMC,	91	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					+	+							LMX		
Esteves Kondo, Det	30	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+												LMX		
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								B57,CW18	LMX			
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+										LMX		
Hamdi, Nuha	87	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+										LMX		
Hardy, Steven PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+									BW6	LMX		
Hogan, Patrick		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+												LMX		
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+											LMX	
Klein, Tirza	24	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					+	+							LMX		
Lardy, N.M.		+	+	+	+	+	+	+	+	+							+						+													LMX	
Mah, Helen		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+														LMX	
Mani, Rama	90	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,B60,B61,B48 >	LMX		
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX	
Meyer, Pieter Wa	24	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+											LMX	
Pancoska, Carol PhD	33	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+										LMX	
Permpikul, Vejbaesy		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+											LMX	
Phelan, Donna		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+											LMX	
Ramon, Daniel PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Rosen-Bronson, Sai	92	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW7	LMX	
Suciu-Foca, Nicole I		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Turner, E.V. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Vather, Nelson/																																				LMX	

**Table 23. Individual laboratory results for Serum #1158 by Luminex**

		**** Serum 1158 ****																																					
Investigator	% POS	A2	A29	A3	A30	A31	A33	A68	A69	A74	B7	B27	B60	B61	CW6	B47	B81	B42	CW7	B13	A34	B48	A32	A66	A25	B67	B55	A80	A36	A11	B56	B73	A24	B8	A6602	Other	Method		
Alvarez, Carretto &	29	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+																	+	CW4,B8101,CW12	LMX	
Brouard, Tabary/PhD	93	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+		+	+	+	+	+		+	+			+	A203,B65,B8101,A2403 >	LMX		
Cecka, J. Michael PhD	85	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+							A203,B8101,A2403,B2708 >	LMX	
Chen, Dong-Feng		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+		+	+	+	+	+		+	+					A203,B8101,A2403,B2708 >	LMX	
Dunn, Paul	100	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,B82,B65,B2708 >	LMX	
Eckels/CPMC,	91	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+						+	B2708,A6601	LMX	
Esteves Kondo, Det	39	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+									B51,B82,B64,B65 >	LMX	
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B51,B82,B64,B65 >	LMX	
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B82	LMX	
Hamdi, Nuha	87	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	BW4,BW6	LMX	
Hardy, Steven PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW8,CW15	LMX	
Hogan, Patrick		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B82,A2403	LMX	
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,B40,B54,B8101 >	LMX	
Klein, Tirza	39	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B2708	LMX	
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B82	LMX	
Mah, Helen		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,B78,B62,B49 >	LMX
Mani, Rama	88	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B82,B59,CW2,A2403	LMX	
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,B40	LMX	
Meyer, Pieter Wa	26	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Pancoska, Carol Ph	46	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Permpikul, Vejbaesy		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A2403	LMX
Phelan, Donna		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,A2403,B2708,A1101 >	LMX
Ramon, Daniel PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B65,B59	LMX
Rosen-Bronson, Sai	99	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A2403,A1101,A1102,A6601	LMX
Suciu-Foca, Nicole I		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B8101,B2708	LMX
Turner, E.V. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Vather, Nelson/																																						LMX	

**Table 24. Individual laboratory results for Serum #1159 by Luminex**

**** Serum 1159 ****																		
Investigator	% POS	A29	A30	A31	A34	A33	A74	A32	A25	A26	A43	A66	A23	A6601	A6602	Other	Method	
Alvarez, Carretto &	40	+	+	+	+	+	+							+	+	+	CW4,A24,B48,B51 >	LMX
Brouard, Tabary/PhD	51	+	+	+	+	+	+	+	+	+	+			+	+	+	B8	LMX
Cecka, J. Michael PhD	51	+	+	+	+	+	+	+	+	+	+	+						LMX
Chen, Dong-Feng		+	+	+	+	+	+	+	+	+	+			+	+	+		LMX
Dunn, Paul	28	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Eckels/CPMC,	74	+	+	+	+	+	+	+	+	+	+	+			+	+		LMX
Esteves Kondo, Det	19	+	+	+	+	+	+	+	+	+	+	+	+				B8	LMX
Fort, Marylise																		LMX
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+				LMX
Hamdi, Nuha	51	+	+	+	+	+	+	+	+	+	+	+	+	+			B45,B8	LMX
Hardy, Steven PhD		+	+	+	+	+	+	+	+	+	+	+						LMX
Hogan, Patrick		+	+	+	+	+	+					+					B57,B58,B35	LMX
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+					LMX
Klein, Tirza	51	+	+	+	+	+	+	+							+	+	CW4,A11,A24,A2 >	LMX
Lardy, N.M.		+	+	+	+	+	+										CW4,B77,CW12	LMX
Mah, Helen		+	+	+	+	+	+	+	+	+	+	+	+				B8	LMX
Mani, Rama	64	+	+	+	+	+	+	+	+					+	+	+	CW4,B61,B48,B78 >	LMX
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+	+	+					LMX
Meyer, Pieter Wa	37	+	+	+	+							+					CW4,A24,B15,B48 >	LMX
Pancoska, Carol Ph	18	+	+	+	+	+	+	+	+	+	+	+	+					LMX
Permpikul, Vejbaesy		+	+	+	+	+	+	+				+						LMX
Phelan, Donna		+	+	+	+	+	+	+	+	+	+	+						LMX
Ramon, Daniel PhD		+	+	+	+	+	+	+	+	+	+			+	+			LMX
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+						LMX
Rosen-Bronson, Sai	39	+	+	+	+	+	+	+	+	+	+	+	+					LMX
Suciu-Foca, Nicole I		+	+	+	+	+	+	+	+	+	+		+	+	+			LMX
Turner, E.V. PhD		+	+	+	+	+	+	+	+	+		+		+	+			LMX
Vather, Nelson/																		LMX



**Table 26. Individual laboratory results for Serum #1160 by Flow Cytometry, Elisa, and C1q**

Investigator	**** Serum 1157 ****									**** Serum 1158 ****									**** Serum 1159 ****									**** Serum 1160 ****									Method	
	% POS	A1	A25	A26	A29	A31	A66	A68	Other	% POS	A1	A11	A2	A24	A29	A30	A31	A33	Other	% POS	A25	A29	A30	A31	A32	A33	A34	Other	% POS	A25	A26	A29	A31	A33	A36	A66		Other
Esteves Kondo, Dek	90	+	+	+	+	+	+	+	A69 >	81	+	+	+	+	+	+	+	+	A34 >	65	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A68 >	FC

Investigator	**** Serum 1157 ****									**** Serum 1158 ****									**** Serum 1159 ****									**** Serum 1160 ****									Method	
	% POS	A11	A25	A29	A30	A32	A1	A24	Other	% POS	A25	A29	A3	A74	B61	B65	A2	A30	Other	% POS	A30	A31	A66	A74	A29	A1	A25	Other	% POS	A26	A33	A34	A68	A23	A25	A29		Other
Esteves Kondo, Dek	84	+	+	+	+	+			CW4 >	69	+	+	+	+	+	+	+	+	B49 >	35	+	+	+	+	+			B44 >	66	+	+	+	+	+			B49 >	Elisa
Hahn, Amy B. PhD		+	+	+	+	+	+	+	A26 >		+	+	+	+	+	+	+	+	A31 >		+	+	+	+	+	+	+	A26 >		+	+	+	+	+	+	+	A31 >	Elisa

Investigator	**** Serum 1157 ****									**** Serum 1158 ****									**** Serum 1159 ****									**** Serum 1160 ****									Method		
	% POS	A11	A25	A26	A29	A3	A30	A31	Other	% POS	A2	A29	A3	A30	A31	A33	A6602	A68	Other	% POS	A29	A30	A31	A33	A74			Other	% POS	A25	A26	A33	A34	A66	A68	A69		Other	
Phelan, Donna		+	+	+	+	+	+	+	A32 >		+	+	+	+	+	+	+	+	CW6 >		+	+	+	+	+					+	+	+	+	+	+	+	+	CW7	C1q



**Table 27. Individual laboratory results for Serum #1157-1160 by NIH-Standard and Other - class II**

Investigator	**** Serum 1157 ****			**** Serum 1158 ****					**** Serum 1159 ****					**** Serum 1160 ****					Method
	% POS	DR15	Other	% POS	DR1	DR15	DR7	Other	% POS	DR52	Other	% POS	DR52	Other					
Claas, F.H.J.	46			67	+		+		71	+		79	+		STD				
Fort, Marylise	76			19											STD				
Reed, Elaine F. PhD	44	+		34		+			23			33	+		STD				
Suciu-Foca, Nicole I	42			50					35			20			STD				
Watson, Narelle	27			29					18			5			STD				

Investigator	**** Serum 1157 ****		**** Serum 1158 ****							**** Serum 1159 ****						**** Serum 1160 ****					Method			
	% POS	no antigens assigned	% POS	DQ2	DR15	DR16	DR7	DR9	Other	% POS	DQ7	DR11	DR12	DR13	DR14	Other	% POS	DQ4	DR103	DR11		DR12	DR13	Other
Phelan, Donna			96							58							64						Other	
Reed, Elaine F. PhD			98	+	+	+	+	+		68	+	+	+	+	+	DR8,DR17,DR18,DR52	78	+	+	+	+	+	DR4,DR8,DR14,DR15 >	Other



**Table 29. Individual laboratory results for Serum #1159 by Luminex - class II**

Investigator	% POS	**** Serum 1159 ****																		Method						
		DR11	DR12	DR13	DR14	DR7	DR8	DR9	DQ7	DR17	DR18	DR52	DP18	DPW2	DPW4	DP15	DP11	DP17	DQ2		DPW3	DPW1	DP13	DPW6	Other	
Alvarez, Carretto &	40																									LMX
Brouard, Tabary/PhD	51	+	+	+	+	+	+	+	+	+	+	+				+										LMX
Cecka, J. Michael PhD	51	+	+	+	+	+	+	+	+	+	+	+														LMX
Chen, Dong-Feng		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+			LMX
Dunn, Paul	28	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			DQ4,DP402	LMX
Eckels/CPMC,	74	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								LMX
Esteves Kondo, Det	19																									LMX
Fort, Marylise																										LMX
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+			+								LMX
Hamdi, Nuha	51																									LMX
Hardy, Steven PhD																										LMX
Hogan, Patrick		+	+	+	+	+	+	+	+	+	+	+	+	+	+				+	+	+					LMX
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								LMX
Klein, Tirza	51	+	+	+	+	+	+	+					+	+	+				+	+	+				DR3,DQ3	LMX
Lardy, N.M.																										LMX
Mah, Helen																										LMX
Mani, Rama	64	+	+	+	+	+	+	+	+	+	+	+							+						DR1,DR10,DR16,DQ4	LMX
Martinho, Paiva &																										LMX
Meyer, Pieter Wa	37	+	+	+	+	+	+	+											+						DR3,DQ3	LMX
Pancoska, Carol PhD	18	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DR4	LMX
Permpikul, Vejbaesy		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+									LMX
Phelan, Donna		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ4	LMX
Ramon, Daniel PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ4,DQ6	LMX
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+									LMX
Rosen-Bronson, Sai	39	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	LMX	
Suciu-Foca, Nicole I																										LMX
Turner, E.V. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	DQ4	LMX
Vather, Nelson/		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								DQ6	LMX

**Table 30. Individual laboratory results for Serum #1160 by Luminex - class II**

Investigator	**** Serum 1160 ****																			Method							
	% POS	DQ4	DR11	DR12	DR13	DR16	DR4	DR8	DR14	DR103	DR17	DR18	DR52	DR15	DPW1	DP11	DR51	DP13	DP15		DPW4	DPW5	DQ2	DQ7	DQ9	Other	
Alvarez, Carretto &	8																										LMX
Brouard, Tabary/PhD	40	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+			+					LMX
Cecka, J. Michael PhD	47	+	+	+	+	+	+	+	+	+	+	+	+	+			+							+			LMX
Chen, Dong-Feng		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+						LMX
Dunn, Paul	88	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ8	LMX
Eckels/CPMC,	67	+	+	+	+	+	+	+	+	+	+	+	+		+	+											LMX
Esteves Kondo, Det																											LMX
Fort, Marylise																											LMX
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				+					LMX
Hamdi, Nuha	53																										LMX
Hardy, Steven PhD																											LMX
Hogan, Patrick		+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+			+	+	+	+		LMX
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+				LMX
Klein, Tirza	40	+	+	+	+	+	+	+	+					+										+		DR1,DR3	LMX
Lardy, N.M.																											LMX
Mah, Helen																											LMX
Mani, Rama	84	+	+	+	+	+	+	+	+	+	+	+	+				+							+	DR10	LMX	
Martinho, Paiva &																											LMX
Meyer, Pieter Wa	12	+	+	+	+	+	+	+															+		DR3,DQ3	LMX	
Pancoska, Carol Ph	51	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ8	LMX	
Permpikul, Vejbaesy		+	+	+	+	+	+	+	+	+	+	+	+		+	+	+				+						LMX
Phelan, Donna		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ8	LMX
Ramon, Daniel PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ8	LMX
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+								+						LMX
Rosen-Bronson, Sai	84	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+						LMX
Suciu-Foca, Nicole I																											LMX
Turner, E.V. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ8	LMX
Vather, Nelson/		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				DPW6	LMX	



*This is the last report for 2014. Happy Holidays!  
Arlene, Maria, Ching, Belen, Andrea, George, David, and Fadi*



**NEXT MAILING DATE: February 4, 2015**  
*Arlene Locke, David Gjertson, Qiheng Zhang, and Elaine F. Reed*